XL092 (Synonyms: XL092) |
Catalog No.GC62266 |
XL092 est un inhibiteur actif par voie orale et compétitif pour l'ATP de plusieurs récepteurs tyrosine kinases (RTK), y compris MET, VEGFR2, AXL et MER, avec des IC50 dans des dosages cellulaires de 15 nM, 1,6 nM, 3,4 nM, 7,2 nM respectivement. XL092 présente une activité antitumorale. XL092 a le potentiel pour la recherche sur les maladies et affections dépendantes des kinases.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2367004-54-2
Sample solution is provided at 25 µL, 10mM.
XL092 is a potent inhibitor of the activity of Axl, Mer and C-Met kinase with IC50s of <10 nM, respectively. XL092 exhibits anti-tumor activity and has the potential for kinase-dependent diseases and conditions research[1].
XL092 (compound 8; 3 mg/kg; iv) has a T1/2 of 5.4 hours, a CL of 43 mL/hr•kg. XL092 (3 mg/kg; po) has a T1/2 of 7.1 hours and a Cmax of 11.4 μM for rats[1].
[1]. Lynne Canne Bannen, et al. Compounds for the treatment of kinase-dependent disorders. WO2019148044A1.
Average Rating: 5
(Based on Reviews and 37 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *